Université Paris Cité, Service d'Oncologie Médicale, Hôpital Européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
Université Paris Cité, Service d'Oncologie Médicale, Hôpital Européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.
Eur Ann Otorhinolaryngol Head Neck Dis. 2024 Aug;141(4):231-234. doi: 10.1016/j.anorl.2024.02.003. Epub 2024 Feb 27.
Analysis of rechallenge with nivolumab as 5th-line therapy for locally and nodally failed laryngeal squamous cell carcinoma following conventional therapeutic modalities: radiotherapy, surgery and chemotherapy.
A 70-year-old male, with local and nodal progression of laryngeal squamous cell carcinoma after treatment with chemoradiotherapy and surgery, was initially treated for recurrence with carboplatin, 5-fluorouracile (FU) and cetuximab, followed by second-line nivolumab, and then two lines of conventional chemotherapy with paclitaxel and cetuximab followed by carboplatin and cetuximab. He underwent rechallenge with nivolumab in 5th line, achieving 12months' response, ongoing at the time of writing, and 42.5months' survival since initiation of exclusive systemic management after failure of conventional treatment.
This case report highlights the benefit of nivolumab rechallenge in 5th line following previous failure as stand-alone therapy in 2nd line for a patient with laryngeal squamous cell carcinoma locally and nodally uncontrolled after conventional treatment. Clinical trials evaluating the efficacy of this approach are necessary to assess its contribution, as it is currently not a standard therapeutic option.
分析局部和淋巴结失败的喉鳞状细胞癌患者在接受常规治疗方法（放疗、手术和化疗）后，使用纳武利尤单抗作为第 5 线治疗的再挑战。
一名 70 岁男性，在接受放化疗和手术后发生喉鳞状细胞癌局部和淋巴结进展，最初使用卡铂、5-氟尿嘧啶（FU）和西妥昔单抗治疗复发，然后使用二线纳武利尤单抗，然后使用紫杉醇和西妥昔单抗进行两线常规化疗，然后使用卡铂和西妥昔单抗。他在第 5 线接受纳武利尤单抗再挑战，取得了 12 个月的缓解，目前仍在持续，自常规治疗失败后开始单独进行全身治疗以来，已经存活了 42.5 个月。
本病例报告强调了在常规治疗失败后，作为二线治疗的单独治疗药物，纳武利尤单抗在第 5 线再挑战的益处，适用于局部和淋巴结不受控制的喉鳞状细胞癌患者。有必要开展评估该方法疗效的临床试验，以评估其贡献，因为目前它不是一种标准的治疗选择。
